In CORE I, budesonide MMX 9 mg achieved significantly higher remission rates (17.9%) compared to placebo (7.4%, P = 0.0143), while the 6 mg dose did not reach statistical significance.
← all excerpts
Second United Arab Emirates consensus guidance on the diagnosis and management of inflammatory bowel disease.
2
—
—
The sentences
While higher maintenance dosing (40 mg weekly) in SERENE UC showed a trend toward improved remission at week 52, this did not reach statistical significance, and the exploratory TDM arm did not outperform fixed dosing.